AKT/mTORC pathway in antiphospholipid-related vasculopathy: a new player in the game.

about

Antiphospholipid syndrome: an update.Antiphospholipid antibody-induced cellular responses depend on epitope specificity : implications for treatment of antiphospholipid syndrome.Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances.

P2860

Q38410376-5ECB7C95-5409-49BF-96E5-6813A862A4A5 Q47662342-418B2777-927A-4F92-8AC4-2754F59142E1 Q47998109-5DAD436B-3C24-446F-8A67-29CDA46DA81D

P2860

AKT/mTORC pathway in antiphospholipid-related vasculopathy: a new player in the game.

Item

http://www.wikidata.org/entity/Q55068368

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

AKT/mTORC pathway in antiphospholipid-related vasculopathy: a new player in the game.

@en

AKT/mTORC pathway in antiphospholipid-related vasculopathy: a new player in the game.

@nl

type

Item

label

AKT/mTORC pathway in antiphospholipid-related vasculopathy: a new player in the game.

@en

AKT/mTORC pathway in antiphospholipid-related vasculopathy: a new player in the game.

@nl

prefLabel

AKT/mTORC pathway in antiphospholipid-related vasculopathy: a new player in the game.

@en

AKT/mTORC pathway in antiphospholipid-related vasculopathy: a new player in the game.

@nl

P1476

AKT/mTORC pathway in antiphospholipid-related vasculopathy: a new player in the game.

@en

P2093

C Legendre

http://www.w3.org/2001/XMLSchema#string

F Terzi

http://www.w3.org/2001/XMLSchema#string

G Canaud

http://www.w3.org/2001/XMLSchema#string

P2860

Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity

AKT/PKB signaling: navigating downstream

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

The pathogenesis of atherosclerosis: a perspective for the 1990s

A novel pathway for human endothelial cell activation by antiphospholipid/anti-β2 glycoprotein I antibodies.

Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes.

Donor MHC and adhesion molecules in transplant arteriosclerosis.

Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.

Local medial microenvironment directs phenotypic modulation of smooth muscle cells after experimental renal transplantation.

The pathogenesis of the antiphospholipid syndrome.

P304

227-230

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1177/0961203315569336

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

271596576

http://www.w3.org/2001/XMLSchema#string

P698

25631854

http://www.w3.org/2001/XMLSchema#string

AKT/mTORC pathway in antiphospholipid-related vasculopathy: a new player in the game.

about

P2860

P2860

AKT/mTORC pathway in antiphospholipid-related vasculopathy: a new player in the game.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698